| Autor: |
Hossein Haghaei, Somaieh Soltani, Seyedrafie Aref Hosseini, Mohammad Reza Rashidi, Saeed Karima |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Pharmaceutical Sciences, Vol 27, Iss 1, Pp 14-31 (2021) |
| Druh dokumentu: |
article |
| ISSN: |
2383-2886 |
| DOI: |
10.34172/PS.2020.25 |
| Popis: |
Biological activity of Boswellia extract (BE) has been attributed to its main active ingredients; i.e. Boswellic acids (BAs). BE/BAs possess a promising therapeutic potential in neurodegenerative disorders; including Alzheimer's disease (AD). The multifactorial nature of AD pathophysiology necessitates the development of the disease-modifying agents (DMA). Recent multi-targeting approaches for the DMAs development have brought more attention to the plant-derived compounds regarding their better human compatibility because of their biologic origin. This review addresses the current knowledge on the anti-AD activity of BE/BAs based on the available in silico, in vitro, in vivo studies and clinical trials. The contribution of BE/BAs in inflammatory pathways, Tau and β-amyloid proteins, microtubule functions, oxidative stress, cholinesterase and diabetes/insulin pathways involved in AD have been discussed. BAs efficacy in different AD-related pathways has been confirmed in vitro and in vivo. They can be considered as valuable scaffold/lead compounds for multi-targeted DMAs in anti-AD drug discovery and development. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
